姜黄素通过过氧化物酶体增生物激活受体-γ在大鼠实验性结肠炎中发挥抗炎作用

背景：研究显示姜黄素可激活过氧化物酶体增生物激活受体（PPAR）-γ，抑制三硝基苯磺酸（TNBS）诱导的大鼠结肠炎症。目的：以姜黄素和PPAR-γ拮抗剂GW9662单独或联合干预结肠炎模型大鼠，探讨姜黄素在大鼠实验性结肠炎中的抗炎机制。方法：以直肠内注入TNBS／乙醇溶液制备大鼠结肠炎模型。模型大鼠分别腹腔注射二甲基亚砜（DMSO）、姜黄素、GW9662或GW9662＋姜黄素2周，评价各组大鼠的死亡率、结肠损伤评分、血清促炎因子白细胞介素（IL）-2和抗炎因子IL-10水平以及结肠组织PPAR-γ和核因子（NF）-κB的表达。结果：与模型对照组相比，姜黄素能明显降低大鼠死亡率、结肠黏膜大体、组织学损伤评分和血清IL-2水平，升高血清IL-10水平，结肠组织PPAR-γ表达增高，NF-κB表达减低（P〈0．05）；GW9662＋姜黄素组大鼠结肠炎症无明显改善。正常对照组、模型对照组和姜黄素组PPAR-γ与NF-κB的表达均呈负相关（P〈0．01）。结论：姜黄素可通过PPAR-γ途径负性调节NF-κB的表达，在TNBS诱导的大鼠结肠炎中发挥抗炎作用。     

Faecalibacteriumprausnitzii对实验性结肠炎大鼠Foxp3＋Treg细胞的影响

Fxop3＋Treg细胞是-种免疫调节细胞,在免疫调节和维持机体免疫平衡中起重要作用。目的：研究Faecalibacterium口删nitzii（FP）对实验性结肠炎大鼠外周血和脾脏中CD4＋CD25＋Foxp3＋Treg细胞的影响,从而初步探讨FP治疗溃疡性结肠炎（UC）的作用机制。方法：采用2,4,6-三硝基苯磺酸（TNBS）灌肠制备实验性结肠炎大鼠模型．将大鼠随机分为正常对照组、结肠炎组、FP组、FP上清液组、培养基组和双歧杆菌组。观察大鼠结肠大体形态损伤、组织学变化．以流式细胞术测定外周血和脾脏中CD4＋CD25＋Foxp3＋rreg细胞比例,以ELISA法检测血浆IL-10、IL-12和TGF．B含量。结果：与正常对照组相比,结肠炎组结肠大体形态损伤明显,病理学评分显著增高（P〈O．01）;外周血和脾脏中CD4＋CD25＋Foxp3＋Treg细胞比例显著降低（P〈O．05）;血浆IL．10和TGF．B含量显著降低（P〈0．05）,IL-12含量显著升高（P〈O．01）,IL-IO／IL-12比值显著降低（P〈0．01）。经FP、FP上清液和双歧杆菌治疗后,除血浆IL-10含量无明显差异外．其余指标均显著改善（P〈0．05）。结论：FP及其上清液对TNBS诱导的实验性结肠炎大鼠有显著的治疗作用．其机制可能为提高外周血和脾脏中CD4＋CD25＋Foxp3＋Treg细胞比例。     

IL-10对急性坏死性胰腺炎大鼠NF—κB及IL-12水平的影响

目的观察白介素10（IL-10）对ANP大鼠NF—κB和IL-12表达的影响，探讨IL-10的作用机制。方法将92只SD大鼠按随机分组法分为对照组、ANP组和IL-10干预组。采用3次腹腔注射左旋精氨酸（1．0mg／g体重）的方法制备ANP模型。对照组腹腔注射等量生理盐水。IL-10组在制模后2、5、8h分别于腹腔内注射IL-10 10 000U。制模后4、12、24、36h分批处死动物，观察血清淀粉酶、IL-12及胰腺组织NF—κB水平的变化。结果制模后24h点IL-10组胰腺病理分值为4．75±1．75，胰腺NF—κB含量为（112．89±34．48）μg/ml，血清淀粉酶含量为（1481．13±336．48）U／L，血清IL-12水平为（81．31±17．23）pg／ml，均明显低于同时点ANP组大鼠（P〈0．05或P〈0．01）。NF—κB和IL-12呈正相关（r=0．494，P〈0．01），两者与胰腺病理分值也呈正相关（r=0．447和r=0．603，P〈0．01）。结论IL-10对ANP有一定的治疗作用，其机能可能通过抑制NF—κB途径而抑制ANP的炎症反应。     

康复新液对小鼠嗯唑酮结肠炎的疗效及其机制初探

我国溃疡性结肠炎的发病率不断升高,现有治疗尚存在不足,需寻找新的治疗方法和药物。目的：观察康复新液对小鼠嗯唑酮（OXZ）结肠炎的疗效,初步探讨其治疗机制。方法：将60只小鼠随机分为空白对照组、模型组、康复新液组、高浓度康复新液组、激素组,以OXZ灌肠诱导结肠炎模型。分别于灌肠后第3、8、13d处死小鼠。行疾病活动指数（DAI）、结肠大体评分和组织学评分,以ELISA法检测结肠组织髓过氧化物酶（MPO）、白细胞介素4（IL4）、干扰素．1（IFN-1）、肿瘤坏死因子．Or．（TNF—d）、NF—KB含量。结果：灌肠后第3、13d,与空白对照组相比,模型组DAI、结肠大体评分、组织学评分、MPO、IL-4、TNF-d、NF—KB含量均明显升高（P〈0．05）,IFN．1含量无明显差异。灌肠后第8、13d,给予康复新液和高浓度康复新液治疗后,上述指标均明显改善（P〈0．05）,IFN-y含量无明显差异。灌肠后第8d,激素组仅大体评分和IL-4含量明显降低（P〈0．05）。结论：康复新液灌肠可使OXZ诱导的小鼠结肠炎症明显减轻,其作用可能与抑制肠道异常炎症反应、调节细胞因子水平、抑制NF—KB转录有关。     

实验性结肠炎p38丝裂原活化蛋白激酶表达的研究

目的观察三硝基苯磺酸（TNBS）诱导的大鼠结肠炎结肠组织p38MAPK表达与激活及大鼠血清TNF-α、IL-10水平变化,探讨p38MAPK在实验性结肠炎中的作用与机制。方法20只SD大鼠随机分为正常对照组（N）与模型组（M）,TNBS／乙醇法构建结肠炎模型,观察炎症活动指数（DAI）、大体形态损伤指数（CMDI）、组织学损伤指数（TDI）,ELISA法检测血清TNF-α、IL-10水平,免疫组化染色检测大鼠结肠p38MAPK、p-p38MAPK表达。结果与N组相比,M组DAI、CMDI、TDI显著升高（P〈0．01）,血清TNF-α升高,IL-10水平下降（P〈0．01）,结肠组织p38MAPK表达增加（P〈0．05）,p-p38MAPK表达显著增加（P〈0．01）。结论p38MAPK在实验性结肠炎的表达与激活均有明显增加,可能通过调节TNF-α、IL-10等细胞因子的表达参与结肠炎的发病。     

化瘀解毒法对溃疡性结肠炎大鼠血清IL-4和IL-10水平的影响

目的 探讨化瘀解毒中药防治溃疡性结肠炎的作用机理.方法 将40只Wistar大鼠随机分为正常组、空白对照组、中药组和柳氮磺吡啶组,每组10只.应用2,4,6-三硝基苯磺酸(TNBS)复制溃疡性结肠炎动物模型,中药组给予化瘀解毒中药汤剂灌胃,柳氮磺吡啶组给予柳氮磺吡啶灌胃,正常组及空白对照组灌服等体积蒸馏水.21 d后观察大鼠结肠大体形态学及组织病理学改变,采用ELISA法检测各组大鼠的血清IL-4和IL-10水平.结果 化瘀解毒中药能有效提高溃疡性结肠炎大鼠血清IL-4和IL-10水平,并对损伤的大肠黏膜有明显修复作用.结论 化瘀解毒中药能够促进抗炎因子IL-4和IL-10的产生和表达,并对大鼠实验性溃疡性结肠炎疗效显著,说明该法对血清IL-4和IL-10的调节作用可能是其治疗机制之一.     

弓形虫感染对大鼠脑组织神经丝mRNA表达的影响

目的探讨弓形虫感染对大鼠脑组织神经丝（NF）mRNA表达和细胞免疫水平的影响。方法将4周龄雄性SD大鼠随机分成2组：弓形虫感染组（A组）腹腔感染弓形虫速殖子2×10^2／ml悬液2ml;正常对照组（B组）腹腔注射灭菌生理盐水2ml。感染弓形虫速殖子9周后,应用逆转录聚合酶链反应检测大鼠大脑组织中高分子量NF（NF—H）、中分子量NF（NF—M）和低分子量NF（NF—L）mRNA表达水平;流式细胞术检测大鼠外周血CD3^＋、CD4^＋、CD8^＋T淋巴细胞;ELISA测定其血清IFN-γ、TNF-α、IL-4等细胞因子。结果大鼠弓形虫感染9周后,大脑组织NF．LmRNA下降为正常对照组的64％（P〈0．01）;NF—M为96％（P〉0．05）;NF—H为89％（P〈0．05）。感染组大鼠的CD4^＋和CD8^＋T淋巴细胞与正常对照组相比,差异均无统计学意义（P均〉0．05）;感染组大鼠血清中IFN-γ、TNF-α、IL-4等细胞因子的水平均高于正常对照组大鼠水平（P〈0．05）。结论弓形虫感染可导致大鼠脑组织中NF亚单位mRNA表达水平的下降,血清IFN-γ、TNF-α、IL-4水平的升高。     

复方黄柏液对大鼠TNBS结肠炎的治疗机制探讨

背景：临床上采用复方黄柏液保留灌肠辅助治疗溃疡性结肠炎（UC）疗效满意,但其作用机制尚不清楚。目的：探讨复方黄柏液对三硝基苯磺酸（TNBS）诱发的大鼠结肠炎模型炎症损伤的治疗作用及其可能机制。方法：40只成年雌性Sprague-Dawley大鼠随机分成四组,正常对照组不予处理,其余三组以TNBS／乙醇溶液灌肠制作结肠炎模型后．分别予0．9％NaCl溶液1ml、5-氨基水杨酸（5-ASA）200mg／kg和复方黄柏液1ml灌肠,连续14d。治疗后评估大鼠疾病活动指数（DAI）以及结肠大体、组织学损伤情况;检测结肠组织髓过氧化物酶（MPO）活性和白三烯B4（LTB4）含量;心脏采血,流式细胞术检测中性粒细胞凋亡率。结果：与正常对照组相比,TNBS模型组DAI、结肠大体和组织学评分、结肠组织MPO活性和LTB。含量均显著升高,血中性粒细胞凋亡率显著降低（P〈0．01）;5-ASA治疗组和复方黄柏液治疗组上述指标均较TNBS模型组显著改善（P〈0．01）,两组间差异则无统计学意义。结论：复方黄柏液灌肠对大鼠TNBS结肠炎具有明显治疗作用,促进中性粒细胞凋亡、清除结肠局部损伤因子（MPO、LTB。）可能为其作用机制之一。     

白介素17在三硝基苯磺酸诱导结肠炎小鼠结肠内的表达及益生菌的作用

目的评价IL-17在TNBS（三硝基苯磺酸）诱导结肠炎小鼠结肠中的表达情况及益生菌对IL-17的影响。方法双歧三联活菌干预组（B IFICO组）与阴性对照组（TNBS组）小鼠自实验前5天起分别给予双歧三联活菌混悬液或PBS灌胃,实验当天及实验后第5天给予TNBS/乙醇溶液灌肠,实验第7天处死。处死后行组织学评分评价结肠炎症情况,并以免疫组化方法评价结肠内IL-17的表达情况。结果 B IFICO组小鼠结肠组织学评分低于TNBS组（2.11±0.78vs3.22±0.97,P〈0.05）。IL-17在上皮细胞中表达程度评分,TNBS组明显高于正常对照组（8.00±0.82vs3.50±0.55,P〈0.01）,B IFICO组低于TNBS组（6.78±0.83vs8.00±0.82,P〈005）;固有层中IL-17阳性细胞计数,TNBS组明显高于正常对照组（10.74±2.78vs0.90±0.70,P〈0.01）,B IFICO组低于TNBS组（4.07±1.39vs10.74±2.78,P〈0.01）。结论 TNBS诱导结肠炎的小鼠结肠内IL-17表达明显增加,双歧三联活菌可能通过抑制IL-17的表达减轻小鼠的实验性结肠炎。     

青白栓抗大鼠溃疡性结肠炎的实验研究

[目的]探讨青白栓对大鼠溃疡性结肠炎（UC）的治疗作用。[方法]采用二硝基氯苯和乙酸复合方法制备大鼠UC模型，经病理切片证实造模成功后，随机分为5组，青白栓高、中、低剂量组，模型组和柳氮磺吡啶栓组。各组大鼠根据其分组分别给予相应的处理20d后，检测各组大鼠结肠组织中超氧化物歧化酶（SOD）、丙二醛（MDA）和血清白细胞介素2（IL-2）、白细胞介素6（IL-6）、肿瘤坏死因子α（TNF-α）、IgA、IgM、体重及肠重指数的变化。[结果]青白栓高、中剂量组动物组织中SOD显著降低，MDA显著下降（P〈0．01），青白栓高剂量组动物血清中IL-2、IL-6、TNF-α均显著降低（P〈0．05，〈0．01）。[结论]青白栓可有效地用于实验性UC的治疗。     

实验性结肠炎大鼠内毒素-Toll样受体4-核因子κB信号通路的变化及益生菌的作用

目的探讨和分析实验性结肠炎大鼠血浆内毒素水平的变化及结肠Toll样受体4（TLR4）和核因子κB（NF-κB）表达及意义,并分析益生菌的作用。方法30只雄性W istar大鼠均分为正常对照组（NC组）、模型对照组（UC组）和益生菌治疗组（PC组）;UC和PC组建立2,4,6-三硝基苯磺酸（TNBS）实验性结肠炎大鼠模型,PC组大鼠给予双歧三联活菌悬液（2.2×10^9CFU/只）治疗,1次/d,共4周。光镜下观察肠黏膜炎性反应并评分;鲎试验检测各组大鼠血浆内毒素水平;W estern印迹法和实时荧光定量PCR法检测大鼠结肠TLR4和NF-κB p65蛋白及mRNA的表达,分析其变化及益生菌的作用。结果PC组炎性反应评分较UC组明显降低（P〈0.05）,但高于NC组（P〈0.01）;PC组血浆内毒素明显低于UC组（P〈0.05）,但高于NC组（P〈0.01）;UC组TLR4和NF-κB p65的蛋白及mRNA表达明显高于PC组和NC组（P〈0.05、0.01）,PC组高于NC组（P〈0.01）。结论内毒素-TLR4-NF-κB信号通路参与了大鼠实验性结肠炎的发生和发展,减少内毒素的产生、降低大鼠结肠TLR4和NF-κB表达可能是益生菌减轻大鼠结肠炎症的机制之一。     

徐长卿对三硝基苯磺酸诱导的大鼠结肠炎的作用

目的:探讨徐长卿对2,4,6-三硝基苯磺酸(trinitrobenzenesulfonic acid,TNBS)诱导的大鼠结肠炎的作用.方法:将40只♂SD大鼠随机分为4组:正常组、模型组、徐长卿组和巴柳氮组.除正常组外,其余3组大鼠均以TNBS灌肠造模.灌肠24h后,徐长卿组开始每天给予徐长卿4g/kg;巴柳氮组给予巴柳氮钠1g/kg灌胃治疗10d.每天观察大鼠一般情况,给药结束后,观察大鼠结肠大体损伤及病理,酵素免疫分析法(enzyme-linked immunosorbant assay,ELISA)检测肠组织肿瘤坏死因子(tumor necrosis factor,TNF)-α、白介素(interleukin,IL)-1β及IL-10水平.结果:两治疗组体质量较模型组增加,但差异无统计学意义;两治疗组疾病活动指数(disease activity index,DAI)评分较模型组明显下降(0.70±1.06,0.67±0.71vs2.38±1.51,P<0.05).徐长卿组、巴柳氮组结肠大体损伤及病理评分较模型组显著下降(1.05±0.83,1.06±0.85vs2.94±0.94;1.65±1.67,2.00±1.80vs6.00±1.67,均P<0.01).徐长卿组较模型组TNF-α、IL-1β水平明显降低(P<0.01),IL-10水平无统计学差异.巴柳氮组较模型组TNF-α、IL-1β、IL-10水平均明显降低(P<0.01).结论:徐长卿能有效改善TNBS诱导的大鼠结肠炎,其机制可能与调节细胞因子水平有关.     

生长抑素对溃疡性结肠炎模型大鼠肠道炎性损伤的治疗作用

目的: 观察生长抑素(奥曲肽)对溃疡性结肠炎(ulcerative colitis,UC)大鼠模型的作用,初步探讨其可能机制.方法: ♂SD大鼠随机分为正常对照组、奥曲肽对照组、模型组、治疗组,每组7只. 模型组、治疗组大鼠用三硝基苯磺酸(TNBS)/乙醇溶液灌肠复制UC模型. 观察各组实验大鼠体质量变化、大体及组织病理学改变. 采用酶联免疫吸附法检测细胞因子(IL-6、IL-10、TNF-α)的含量、蛋白质印迹杂交法检测结肠组织NF-κB p65蛋白的表达.结果: 生长抑素可以缓解大鼠体质量的减轻,减少腹泻及便血的发生,并且能够显著改善结肠组织大体和组织学评分. 与正常组比较,模型组大鼠结肠黏膜IL-6、TNF-α表达明显升高(188.27±11.65 ng/L vs 102.13±7.12 ng/L,87.39±6.74 ng/L vs 121.51±8.56 ng/L,均P<0.01);IL-10表达明显下降(71.40±8.28 ng/L vs 202.97±12.26 ng/L,P<0.01);与模型组比较,治疗组大鼠结肠黏膜IL-6、TNF-α表达均明显降低(142.03±12.68 ng/L,90.87±9.26ng/L,均P<0.01),IL-10表达明显升高(124.07±10.05 ng/L,P<0.01). 模型组结肠组织中NF-κB的蛋白含量明显高于治疗组(1059.60±96.35vs 471.23±11.61,P<0.01).结论: 生长抑素对TNBS诱导的大鼠溃疡性结肠炎具有显著治疗作用,其作用机制可能是通过影响炎症反应的信号通路NF-κB的活化,进而下调促炎细胞因子及上调抗炎细胞因子的产生和表达.     

Expression and significance of nuclear factor κB p65 in colon tissues of rats with TNBS-induced colitis

AIM: To investigate the role of NF-κB in the pathogenesis of TNBS-induced colitis in rats.METHODS: Thirty-two healthy adult Sprague-Dawley (SD)rats were randomly divided into four groups of eight each:normal, NS, model I, model Ⅱ groups in our study. Rat colitis model was established through 2-,4-,6-trinitrobenzene sulfonic acid (TNBS) enema. At the end of four weeks,the macroscopical and histological changes of the colon were examined and mucosa myeloperoxidase (MPO)activities assayed. NF-κB p65 expression was determined by Western blot assessment in cytoplasmic and nuclear extracts of colon tissue, and the expressions of TNF-αand ICAM-1 protein in colon tissue were examined by immunohistochemistry. The relativities between expression of NF-κBp65 and other parameters were analyzed.RESULTS: TNBS enema resulted in pronounced pathological changes of colonic mucosa in model Ⅱ group (macroscopic and histological injury indices 6.25±1.39 and 6.24±1.04,respectively), which were in accordance with the significantly elevated MPO activity (1.69±0.11). And the nuclear level of NF-κB and expression of TNF-α, ICAM-1 in rats of model Ⅱ group were higher than that of normal control (9.7±1.96 vs1.7±0.15, 84.09±14.52 vs16.03±6.21,77.69±8.09 vs13.41±4.91 P＜0.01), Linear correlation analysis revealed that there were strong correlations between the nuclear level of NF-κB and the tissue positive expression of TNF-α and ICAM-1, MPO activities,macroscopical and histological indices in TNBS-induced colitis, respectively (r = 0.8235, 0.8780, 0.8572, 0.9152,0.8247; P＜0.05).CONCLUSION: NF-κB plays a pivotal role in the pathogenesis of ulcerative colitis, which might account for the up-regulation the expression of TNF-α and ICAM-1.     

白细胞介素-23/-17轴在小鼠急性实验性结肠炎中的表达及作用

目的 研究白细胞介素(IL)-23/IL-17轴在小鼠实验性结肠炎结肠组织中的表达和作用.方法 将64只小鼠分为对照组24只、模型组24只、抗体组8只、正常血清组8只.除对照组外,其余各组建立小鼠急性实验性结肠炎模型.对照组和模型组小鼠分别于造模后24 h、48 h、7 d处死.抗体组和正常血清组小鼠分别于造模前2 h腹腔内注射多克隆大鼠抗小鼠IL-17中和抗体和正常大鼠血清,于造模48 h后处死.检测各组小鼠组织学损伤评分、肠组织髓过氧化物酶(MPO)活性;酶联免疫吸附试验检测结肠组织IL-23p19、IL-17含量;免疫组化染色检测核因子(NF)-κB p65在结肠组织中的表达;实时荧光定量(RT)PCR检测IL-23p19、IL-17、IL-12p35的mRNA表达水平.结果 模型组24 h、48 h、7 d时IL-23p19蛋白表达水平和mRNA表达水平[分别为(15.53±3.32)、(31.16±4.98)、(14.03±3.56)ng/mg蛋白和4.09±0.34、3.39±0.46、6.54±1.82]、IL-17的蛋白表达水平和mRNA表达水平[分别为(0.35±0.06)、(0.38±0.08)、(0.26±0.05)ng/mg蛋白和4.21±2.61、2.65±0.91、5.63±1.43]均显著高于正常对照组(P值均＜0.05),48 h时达高峰.IL-23与IL-17蛋白表达水平和mRNA表达水平呈正相关(r值分别为0.745和0.793,P＜0.05).抗体组IL-23p19和IL-12p35高水平表达,但NF-κB p65阳性细胞率、组织学评分及MPO活性[分别为1.86%±0.36%、0.63±0.52、(0.40±0.03)U/g]明显低于48 h模型组[分别为4.35%±0.37%、5.13±0.64、(2.29±0.40)U/g],说明中和IL-17后能明显减轻结肠炎症,抑制NF-κB活性.结论 IL-23/IL-17轴在急性实验性结肠炎早期阶段起关键作用.IL-17有望成为炎症性肠病治疗的新靶标.     

美沙拉嗪对2，4，6-三硝基苯磺酸诱导溃疡性结肠炎大鼠脾脏组织NF—κBp65表达的影响

目的 探讨美沙拉嗪对2,4,6-三硝基苯磺酸（TNBS）诱导的溃疡性结肠炎大鼠脾脏组织NF-κB p65表达的影响.方法 将42只SD大鼠随机分为空白对照组、结肠炎模型组和美沙拉嗪治疗组,每组各14只.除空白对照组外,其他两组均应用TNBS灌肠制作溃疡性结肠炎大鼠模型;模型建成2d后,空白对照组和结肠炎模型组均用蒸馏水、美莎拉嗪治疗组用美莎拉嗪蒸馏水混悬液3 mL灌胃;连续灌胃15 d后取脾脏组织,采用RT-PCR法检测NF-κB p65 mRNA,Western blot法检测NF-κB p65蛋白.结果 与空白对照组比较,结肠炎模型组NF-κB p65 mRNA、蛋白表达均升高（P均＜0.05）;与结肠炎模型组比较,美沙拉嗪治疗组NF-κB p65 mRNA、蛋白均下降（P均＜0.05）.结论 美沙拉嗪能通过下调TNBS诱导的溃疡性结肠炎大鼠脾脏组织NF-κB p65的表达,发挥治疗溃疡性结肠炎的作用.     

培菲康对实验性溃疡性结肠炎大鼠TNF-α、IL-10水平的影响

目的阐明培菲康对三硝基苯磺酸钠(TNBS)诱导的大鼠溃疡性结肠炎(UC)TNF-α、IL-10水平的影响,寻求UC治疗的有效新途径。方法成年雌性SD大鼠50只,随机分成5组(n=10):正常对照组(G1)、模型对照组(G2)、培菲康治疗组(G3)、奥沙拉嗪治疗组(G4)、培菲康和奥沙拉嗪联合治疗组(G5),经不同处理和治疗后,通过免疫组化染色观测各组大鼠结肠组织中TNF-α(两步法)、IL-10(S-P法)表达情况,通过实时荧光定量PCR分析结肠组织中TNF-α、IL-10mRNA的表达水平。结果G1组各指标显著低于G2组(P0.001),肠组织结构正常;与G2组相比,G3、G4、G5组TNF-α、IL-10细胞阳性率和TNF-α、IL-10mRNA的表达水平显著降低(P0.001);与G3或G4组相比,G5组TNF-α、IL-10细胞阳性率和TNF-α、IL-10mRNA的表达水平也显著降低(P0.001);G3或G4组之间,TNF-α、IL-10细胞阳性率及TNF-αmRNA水平无差别(P0.05),而G4组IL-10mRNA水平明显低于G3组(P0.001)。结论TNF-α、IL-10在溃疡性结肠炎(UC)的发生、发展过程中起重要作用,培菲康能明显降低该过程中肠组织TNF-α、IL-10的表达水平,可能通过调控这两个细胞因子的表达而发挥疗效。     

Therapeutic and prophylactic thalidomide in TNBS-induced colitis: Synergistic effects on TNF-α, IL-12 and VEGF production

AIM: To evaluated the therapeutic and prophylactic effect of thalidomide on 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. Thalidomide has been reported to downregulate the expression of tumor necrosis factor α (TNF-α), IL-12, and vascular endothelial growth factor (VEGF), hallmarks of intestinal inflammation in Crohn's disease (CD).METHODS: Male Wistar rats were divided in five groups of ten animals each. Four groups received a rectal infusion of TNBS in ethanol. The first group was sacrificed 7 d after colitis induction. The second and third groups received either thalidomide or placebo by gavage and were sacrificed at 14 d. The fourth group received thalidomide 6 h before TNBS administration, and was sacrificed 7 d after induction. The fifth group acted as the control group and colitis was not induced. Histological inflammatory scores of the colon were performed and lamina propria CD4+ T cells, macrophages, and VEGF+ cells were detected by immunohistochemistry. TNF-α and IL-12 were quantified in the supernatant of organ cultures by ELISA.RESULTS: Significant reduction in the inflammatory score and in the percentage of VEGF+ cells was observed in the group treated with thalidomide compared with animals not treated with thalidomide. Both TNF-α and IL-12 levels were significantly reduced among TNBS induced colitis animals treated with thalidomide compared with animals that did not receive thalidomide.TNF-α levels were also significantly reduced among the animals receiving thalidomide prophylaxis compared with untreated animals with TNBS-induced colitis. Intestinal levels of TNF-α and IL-12 were significantly correlated with the inflammatory score and the number of VEGF+ cells.CONCLUSION: Thalidomide significantly attenuates TNBS-induced colitis by inhibiting the intestinal production of TNF-α, IL-12, and VEGF. This effect may support the use of thalidomide as an alternate approach in selected patients with CD.     

Therapeutic and prophylactic thalidomide in TNBS-induced colitis： Synergistic effects on TNF-α, IL-12 and VEGF production

AIM： To evaluated the therapeutic and prophylactic effect of thalidomide on 2, 4, 6-trinitrobenzene sulfonic acid （TNBS）-induced colitis. Thalidomide has been reported to downregulate the expression of tumor necrosis factor α （TNF-α）, IL-12, and vascular endothelial growth factor （VEGF）, hallmarks of intestinal inflammation in Crohn＇s disease （CD）.
METHODS： Male Wistar rats were divided in five groups of ten animals each. Four groups received a rectal infusion of TNBS in ethanol. The first group was sacrificed 7 d after colitis induction. The second and third groups received either thalidomide or placebo by gavage and were sacrificed at 14 d. The fourth group received thalidomide 6 h before TNBS administration, and was sacrificed 7 d after induction. The fifth group acted as the control group and colitis was not induced. Histological inflammatory scores of the colon were performed and lamina propria CD4＋ T cells, macrophages, and VEGF＋ cells were detected by immunohistochemistry. TNF-α and IL-12 were quantified in the supernatant of organ cultures by ELISA.
RESULTS： Significant reduction in the inflammatory score and in the percentage of VEGF＋ cells was observed in the group treated with thalidomide compared with animals not treated with thalidomide. Both TNF-α and IL-12 levels were significantly reduced among TNBS induced colitis animals treated with thalidomide compared with animals that did not receive thalidomide. TNF-α levels were also significantly reduced among the animals receiving thalidomide prophylaxis compared with untreated animals with TNBS-induced colitis. Intestinal levels of TNF-α and IL-12 were significantly correlated with the inflammatory score and the number of VEGF＋ cells.
CONCLUSION： Thalidomide significantly attenuates TNBS-induced colitis by inhibiting the intestinal production of TNF-α, IL-12, and VEGF. This effect may support the use of thalidomide as an alternate approach in selected patients with CD.